CTOs on the Move


 
STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

STIMIT raised $20.6M on 12/03/2020

Similar Companies

Aqualung Therapeutics

Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension.

Taiga Biotechnologies Inc

Taiga Biotechnologies is a privately-held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions.

EMD Biosciences

EMD Biosciences, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ansun Biopharm

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. Paradase is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.